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Abstract: Nanostructured lipid carriers (NLCs) loaded with lopinavir (LPV) were prepared by the
high-shear homogenization method. The LPV-NLCs formulations were freeze-dried using trehalose
as a cryoprotectant. In vitro release studies in simulated gastric fluid (pH 1.2) and simulated intestinal
fluid (pH 6.8) showed a burst release. The optimized freeze-dried formulation (LPV-NLC-7-Tres) had
a particle size (PS), polydispersity index (PdI), zeta potential (ZP) and % entrapment efficiency (%EE)
of 286.8 ± 1.3 nm, 0.413 ± 0.017, −48.6 ± 0.89 mV and 88.31 ± 2.04%, respectively. The optimized
formulation observed by transmission and scanning electron microscopes showed a spherical shape.
Differential scanning calorimetry study revealed the absence of chemical interaction between the
drug and lipids. In vitro cellular uptake study using Caco-2 cell line showed a higher LPV uptake
from LPV-NLC-7-Tres formulation compared to the free LPV-suspension. The 6-month stability study
showed a minimum rise of ~40 nm in PS, while no significant changes in PdI, ZP and drug content
of the LPV-NLC-7-Tres formulation stored at 5 ◦C ± 3 ◦C. The bioavailability of LPV following
oral administration of LPV-NLC-7-Tres in male Wistar rats was found 6.98-fold higher than the
LPV-suspension. In conclusion, the nanostructure lipid carriers are potential carriers for improving
the oral bioavailability of lopinavir.
Keywords: lopinavir; lipid-based formulations; cellular uptake; factorial design
1. Introduction
Acquired immune deficiency syndrome (AIDS) is a variety of complications caused by the human
immunodeficiency virus (HIV) infection. HIV is mostly localized and replicated in the cell (monocytes
and CD4+ T lymphocytes), and anatomical (lymphatic system, central nervous system and genitals)
levels. Currently, the majority of the available anti-HIV drugs are suppressing the viral replication
within the peripheral blood circulation [1]. Therefore, targeting the antiretroviral drug to a system that
serves as a viral reservoir will have some advantages with a reasonable approach.
Lopinavir (LPV) is an antiretroviral drug of the protease inhibitor class. It is prescribed as
an effective treatment for HIV-1 infections in a combination therapy [1]. LPV exhibits limited oral
bioavailability due to poor aqueous solubility (0.01 mg/mL), high P-glycoprotein efflux and extensive
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first-pass metabolism by liver microsomal enzyme cytochrome P450 (CYP3A4) [2]. Consequently, LPV
fails to attain sufficient therapeutic concentration in the systemic circulation, when administered alone.
In order to improve the oral bioavailability, LPV is currently marketed as a fixed dose coformulation
with ritonavir, under the names of Aluvia® and Kaletra® [3]. Ritonavir is an analogue of LPV that
enhances the oral bioavailability of LPV due to its inhibitory effect on CYP3A4 and P-gp [3,4].
However, the use of ritonavir in the combination therapy may cause gastrointestinal intolerance,
glucose intolerance, perioral paresthesia and lipid elevation [4]. Hence, it is inevitable to develop LPV
formulation without coadministration of ritonavir to improve the oral bioavailability of LPV.
In recent years, lipid-based nanoformulations such as nanostructured lipid carriers (NLCs) have
shown great potential in delivering the therapeutic agents to the intestinal lymphatic system and to
avoid the first pass metabolism [5,6]. NLCs are employed as an alternative to solid lipid nanoparticles
(SLNs) due to its controlled release properties and greater chemical and physical stability. It minimizes
the limitations of SLNs, including lower drug loading and formulation instability due to polymorphic
modification of similar lipid molecules [7]. Based on Biopharmaceutics Classification System, LPV is a
class II drug, which restricts its absorption via intestinal membrane. NLCs may overcome the solubility
related absorption formulation by enhancing the saturation solubility of loaded LPV and its dissolution.
In addition, NLCs possess more space for drug payload, which may help in reducing the drug dose.
Besides that, NLCs also stimulates the formation of chylomicron in enterocytes which leads to the
absorption of NLCs by the intestinal lymphatic [8]. The instruments and processing steps such as high
shear homogenizer and lyophilizer used in the preparation of stable NLCs formulations can be easily
employed in the pharmaceutical industry for the large-scale production.
In the present study, LPV-NLCs formulation for oral delivery was developed using Compritol
888 ATO® (i.e., glyceryl behenate) as the solid lipid, and oleic acid as the liquid lipid. LPV-NLC
formulations were prepared using hot high shear homogenization methods and optimized statistically
using 24 full factorial design. The formulations were characterized in term of particle size (PS),
polydispersity index (PdI), zeta potential (ZP), percent of entrapment efficiency (%EE) and percent
yield. The selected LPV-NLCs formulations were freeze-dried using cryoprotectant to improve the
stability. In vitro release studies of the selected freeze dried LPV-NLC-Tres formulations were carried
out in alkaline and acidic media. The in vitro cellular uptake of LPV from the optimized LPV-NLC-Tres
formulation was performed using Caco-2 cell lines. The in vivo study was carried out using male
Wistar rats to evaluate the oral bioavailability of LPV.
2. Materials and Methods
2.1. Chemicals
Lopinavir was obtained from Ranbaxy (Mohali, India). Compritol 888 ATO® (glycerol dibehenate
EP- glyceryl behenate NF), was procured from Gattefosse (Saint-Priest, France). Sephadex® G-25,
trehalose and fetal bovine serum (FBS) were procured from Sigma-Aldrich (St. Louis, MO, USA). Oleic
acid was obtained from R&M Chemicals (Essex, UK). Poloxamer 188 (Pluronic® F-68) was purchased
from Molekula (Dorset, UK). Polysorbate 80 (Tween® 80) was purchased from Euro chemo-pharma
Sdn. Bhd. (Penang, Malaysia). The Caco-2 cell line was obtained from ATCC (Manassas, VA,
USA). The Dulbecco’s modified eagle medium (DMEM) and trypsin 0.25% were purchased from
GE healthcare life sciences (Logan, UT, USA). Penicillin-streptomycin solution 100× was obtained
from Biowest (Nuaillé, France). Passive lysis buffer (5×) was purchased from Promega (Madison,
WI, USA).
2.2. Preparation of NLCs and LPV-NLCs
NLCs were prepared using the hot high shear homogenization method [9]. The lipid phase
consisted of Compritol 888 ATO® and oleic acid was melted at 85 ◦C. The aqueous phase consisted of
surfactants (Poloxamer 188 and Tween® 80) at a ratio of 1:1 in double-distilled water was also heated
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to 85 ◦C. The lipid and aqueous phases were mixed and homogenized at 24,000 rpm for 20 or 30 min
using IKA®, T 25 digital Ultra-Turrax® homogenizer (Staufen, Germany). The preparation was then
left to cool at room temperature (25 ◦C ± 2 ◦C) before further characterization.
LPV-NLCs formulations were prepared by adding LPV to the lipid phase. Then the above
procedure was followed to produce LPV-NLCs formulations.
2.3. Optimization of Various Variables using 24 Full Factorial Design
During the preparation of NLCs, the effect of independent variables on the dependent variables
(Table 1) was evaluated and optimized using a 24 full factorial design to find the best combination to
produce the NLCs. The effects of four independent variables (at two levels) such as the homogenization
time (A), concentrations of solid-lipid (B), liquid-lipid (C) and surfactant concentrations (D) on the
dependent variables (i.e., PS, PdI, and ZP) were investigated. Preliminary experiments were carried
out to select the true low and high levels of independent variables.
Table 1. Description of 24 full factorial design.
Factors (Independent Variables) Low Level High Level
A: Homogenization time 20.00 min 30.00 min
B: Solid lipid (compritol 888 ATO®) 270.00 mg 285.00 mg
C: Liquid lipid (oleic acid) 15.00 mg 30.00 mg
D: Surfactants (poloxamer 188: Tween® 80, 1:1) 200.00 mg 300.00 mg
Responses (Dependent Variables) Constraints
PS (nm) Minimize
PdI Minimize
ZP (mV) Maximize
The data obtained were analyzed using the Design Expert software to quantify the effects of
independent variables. The significant effect of each independent variable and their interactions on
dependent variables was evaluated using ANOVA. The experimental data obtained from the dependent
variable response were the results of the effect of independent variables. The data generated from the
two-level experimental design was sufficient to fit the following polynomial Equation (1):
X = β0 + β1A + β2B + β3C + β4D + β12AB + β13AC + β14 AD + β23BC + β24BD + β34CD (1)
where X is a dependent variable, β0 is an intercept term and β1–β34 are coefficients for the independent
factors A, B, C, D and their interactions. 3D response surface plots were generated using factorial 24
modules of design-expert® software.
2.4. Selections of NLCs using the Desirability Function
The desirability function was used for the selection of the NLCs. Accordingly, the obtained
results of responses such as PS, PdI and ZP were fitted into the desirability model of design-expert®
software (Version 11, Stat-Ease, Inc., Minneapolis, MN, USA). The desirability value 1 signifies as an
acceptable value (most desired value) for the responses, while the desirability value 0 signifies as an
unacceptable value
2.5. Characterization of Formulations
Nanoparticulate Properties
The PS and PdI of formulations were measured using Photon Correlation Spectroscopy (PCS)
(Zetasizer 1000HS/3000HS, Malvern Instrument, Malvern, UK). Samples were diluted with filtered,
purified water to weaken the PS and PdI opalescence
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The ZP was determined using Zetasizer Nano series, Nano Z (red badge) (Malvern Instrument,
Malvern, UK). Samples were also diluted with filtered, purified water as above.
2.6. Drug Content Estimation
Free LPV was separated from LPV-NLCs formulations using Sephadex G25 columns. LPV-NLCs
dispersion (1 mL) was placed on the top of the Sephadex G25 column and centrifuged for 2 min at
2000 rpm. The obtained eluent containing LPV-NLCs were freeze-dried using Labconco, FreeZone
Freeze Dry Systems (Kansas City, MO, USA) at −40 ◦C for 24 h. The amount of LPV encapsulated in
the freeze-dried LPV-NLCs sample was analyzed by HPLC.
The HPLC analysis was performed using a Shimadzu chromatography system with LC 20AD
delivery pump (Kyoto, Japan), and a Phenomenex C18 column (250 × 4.60 mm). The mobile phase
consisted of acetonitrile/0.02 M ammonium acetate buffer at a ratio of 65:35 (v/v) with a flow rate of
1 mL/min and a column temperature of 40 ◦C. The injection volume was 20µL and the absorption
wavelength was set at 210 nm.
The % yield was determined by freeze-drying the required amount of LPV-NLC sample and the
weight of freeze-dried LPV-NLCs sample was measured
The percentage entrapment efficiency (% EE) and % yield were calculated using the following
equations:
%EE =
Weight of encapsulated LPV
Initial weight of LPV
× 100 (2)
%Yield =
Weight of NLCs recovered
Initial weight of LPV and excipients
× 100. (3)
2.7. Freeze-Drying Study
2.7.1. Screening of Cryoprotectants
Several cryoprotectants such as mannitol, sorbitol, sucrose and trehalose were screened to
find the best cryoprotectant to protect the LPV-NLC during freeze drying. Different ratios of total
lipids (solid and liquid): cryoprotectant at 1:2, 1:4, 1:6 and 1:8 were studied. The mixture was
freeze-dried using Labconco, FreeZone Freeze Dry Systems (Kansas City, MO, USA) at −40 ◦C for 24 h.
The lyophilized samples were reconstituted in distilled water and analyzed in term of mean PS and
PdI. The cryoprotectant, that produced the smallest PS and PdI was selected for further study.
2.7.2. Method of Cryoprotectant Addition
Two different methods of cryoprotectant addition into the LPV-NLCs formulation were
investigated for the screening of the best lipid and cryoprotectant ratios. In the first method, the selected
cryoprotectant was added after homogenization. The LPV-NLCs formulation (2 mL) was mixed
with the cryoprotectant at lipids: cryoprotectant ratios of 1:2, 1:4, 1:6 and 1:8 w/w. The LPV-NLC
formulations were freeze-dried using Labconco, FreeZone Freeze Dry Systems (Kansas City, MO,
USA) at −40 ◦C for 24 h. In the second method, the selected cryoprotectant was added during the
homogenization process. The required amount of cryoprotectant was dissolved in the aqueous phase.
The mixture was added to the lipid phase and then homogenized to produce LPV-NLCs formulation.
The formulation was freeze-dried and characterized.
2.8. In Vitro Release Study
In vitro release studies of LPV from the selected freeze-dried formulations (LPV-NLC-Tres) were
performed under sink condition for 12 h in simulated gastric fluid (SGF) (pH 1.2) and simulated
intestinal fluid (SIF) (pH 6.8) both without the enzyme, but containing 1% poloxamer 188 [10,11].
The LPV-NLC-Tres containing 3 mg of LPV were placed in the 150 mL dissolution media and
magnetically stirred at a rate of 100rpm and temperature of 37.5 ± 0.5 ◦C. Samples were withdrawn at
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predetermined time intervals. After each sampling, the same volume of fresh dissolution media was
added to maintain the sink condition. For comparison, a similar procedure of in vitro release study
was also conducted for LPV suspension containing 0.5% w/v methylcellulose as a suspending agent.
The LPV concentrations in the samples were determined using HPLC. The LPV-NLC-Tres formulation,
which showed the highest release of LPV was chosen for further study
2.9. Differential Scanning Calorimetry (DSC)
DSC was performed using a Perkin-Elmer Pyris 6 DSC (Beaconsfield, UK). The required amount
of samples was weighed in an aluminum pan and then sealed using crimper press (Perkin-Elmer;
Beaconsfield, UK). The samples were scanned at the rate of 10 ◦C/min from 0 to 150 ◦C by purging
helium at the rate of 20 mL/min. All samples were scanned in triplicate.
2.10. Powder X-ray Diffraction Analysis (PXRD)
The PXRD θ/2θ analysis was performed using powder X-ray diffractometer (High-resolution
X-ray diffractometer system; model: PANalytical X’Pert PRO MRD PW3040; Almelo, Netherlands)
applying Cu Kα radiation. The samples were subjected to run at a heating rate of 5 ◦C/min, over a
temperature range of 2–60 ◦C.
2.11. Investigations using an Electron Microscope
A sample of LPV-NLCs in a form of liquid (before freeze drying) was smeared on a copper grid
(400 mesh) followed by 2% phosphotungstic acid negative staining, then air dried. The morphology
of the sample was visualized by transmission electron microscopy (TEM) (Philips CM12; Eindhoven,
Netherlands).
The freeze-dried LPV-NLCs without trehalose and optimized LPV-NLC-Tres samples were
separately mounted on an aluminum stub and coated with gold in a sputtering device at 15 mA
for 15 min. The morphology of the sample was examined using scanning electron microscopy (SEM)
(Leo Supra 50 VP field Emission SEM, Carl-Zeiss SMT; Oberkochen, Germany).
2.12. Cellular Uptake Study
The Caco-2 cells of passages between 20 and 25 were used in this experiment. Three different
dilutions of the optimized LPV-NLC-Tres were prepared in DMEM media (without antibiotic and
serum), which comprised of 8.52, 12.79 and 25.58 µg of LPV per 200 µL. Similar dilutions were prepared
for the LPV suspension as a control. The Caco-2 cells were seeded in 48-well plates, at a density of
60,000 cells per well with DMEM complete media until the growth of cells becomes 85% or more
confluent and formed the monolayer. Subsequently, the DMEM complete media inside the wells was
replaced with the prepared dilutions of optimized LPV-NLC-Tres and LPV-suspension, then incubated
at 37 ◦C for 6 h. After the incubation, the test samples were pipetted out from each well and Caco-2
monolayer was washed with phosphate-buffered saline (PBS) for three times to remove residual test
samples and dead cells. The absorbed LPV in the Caco-2 cells was extracted by adding 0.2 mL of
passive lysis buffer and followed by 0.2 mL methanol into each well. The mixtures were transferred
into Eppendorf tubes, then centrifuged at 12,000 rpm for 10 min to separate the lysed Caco-2 cells.
The supernatants were collected and LPV concentration was determined by HPLC.
2.13. Oral Bioavailability Study
The oral bioavailability study was carried out using male Wister rats weighing 250± 20 g. The rats
were kept under controlled laboratory conditions at 25 ± 2 ◦C and 60 ± 5% RH. The rats were retained
in the polypropylene cages, with free access to standard laboratory diet and drinking water. The rats
were fasted overnight before the experiment. The entire procedures of the experiment were approved
by the Animal Ethics Committee Universiti Sains Malaysia, Penang, Malaysia (USM/Animal Ethic
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Approval/2014/(604). Two groups of animals with each group containing 6 rats were used for the
study [11]. The first group was given the optimized LPV-NLC-Tres formulation and the second group
was given the LPV-suspension. The optimized LPV-NLC-Tres formulation and LPV-suspension were
administered orally at a dose of 12 mg/kg of LPV. Blood samples (0.3 mL) were withdrawn from the
tail vein at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h, post oral administration. The samples were transferred
into heparinized Eppendorf tubes, then centrifuge at 5000 rpm for 15 min. The separated plasma
was stored in a deep freezer (−80 ◦C) for further analysis by HPLC method to determine the LPV
concentration in the rat plasma. The LPV detection was performed at 210nm, using a Phenomenex C18
(250 × 4.60 mm, 5 µ) column. Acetonitrile/0.02 M ammonium acetate buffer in a ratio of 65:35 (v/v)
was used as a mobile phase at a flow rate of 1 mL/min and a column temperature of 40 ◦C. The plasma
sample (0.1 mL) was mixed with 500 µL of acetonitrile in an Eppendorf tube followed by addition
of 50 µL mefenamic acid as an internal standard. The obtained mixture was vortexed for 2 min and
centrifuged for 15 min at 5000 rpm to separate the organic phase from the plasma sample residue.
The organic phase was collected in a V-vial and then evaporated under nitrogen gas. The dried residue
was dissolved in 100 µL acetonitrile and vortexed for 2 min followed by centrifugation for 5 min at
12000 rpm. The supernatant was collected and 20 µL was injected into the HPLC system to analyze the
LPV concentration in the plasma sample.
2.14. Stability Studies
The stability study of the optimized freshly prepared freeze-dried LPV-NLC-Tres formulation
was carried out according to the ICH guidelines Q1A(R2). The samples were packed in tightly closed
vials and stored at the three different conditions 5 ± 3 ◦C (refrigerator), 25 ± 2 ◦C/60 ± 5% RH
(room condition), and 40 ± 2 ◦C/75 ± 5% RH (stability chamber). The stability of the optimized
LPV-NLC-Tres formulation in term PS, PdI, ZP and drug content were examined at 0, 1, 3 and 6 months.
2.15. Statistical Analysis
Statistical data analysis was performed using SPSS® statistical software (Version 22; Armonk, NY,
USA). The pharmacokinetic parameters of formulations studied were determined using PK solutions
2.0® noncompartmental pharmacokinetic data analysis software (Windows 2.0.6, Excel). All values
were expressed as the mean and standard deviation (mean ± SD) and the differences were considered
statistically significant when p < 0.05.
3. Results and Discussion
3.1. The 24 Full Factorial Design
The independent variables such as homogenization time (A), solid lipid (B), liquid lipid (C)
and surfactant concentration (D) were optimized using 24 full factorial design. The effect of
independent variables on the dependent variables i.e., PS, PdI and ZP of NLCs are shown in Table 2.
Equations (4)–(6) show the significant effect of each independent variable and their interaction on
dependent variables. The negative or positive sign before each independent factor and their interaction
in the equations denote negative or positive impact toward the response, respectively.
PS = 123.87 − 18.95A − 10.30 B − 5.10C + 28.59D + 7.24 AB + 8.45 AC − 8.57 AD
+ 17.49BC − 15.96 BD − 5.89CD (4)
PdI = 0.46 + 0.020B + 0.021C + 0.020AC + 0.023BC + 0.011BD + 0.022CD (5)
ZP = −43.84 − 0.79A + 1.06B − 4.04D − 1.59AD − 2.01DC + 3.60BD (6)
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Table 2. Optimization of independent variables and the responses of dependent variables.
Formula
Code
Independent Variables Dependent Variables Responses
(A) Homogenization
Time (min)
(B) Solid
lipid (mg)
(C) Liquid
lipid (mg)
(D) Surfactant
(mg) PS (nm) PdI ZP (mV)
NLC-1 20 270 15 200 90.47 ± 2.55 0.44 ± 0.01 −36.4 ± 0.65
NLC-2 30 270 15 200 77.68 ± 2.29 0.44 ± 0.02 −33.2 ± 0.91
NLC-3 20 285 15 200 116.96 ± 4.09 0.52 ± 0.01 −42.9 ± 1.66
NLC-4 30 285 15 200 87.20 ± 1.79 0.42 ± 0.01 −41.6 ± 2.92
NLC-5 20 270 30 200 105.27 ± 11.29 0.45 ± 0.02 −40.3 ± 4.36
NLC-6 30 270 30 200 102.07 ± 32.26 0.39 ± 0.08 −38.0 ± 1.50
NLC-7 20 285 30 200 109.96 ± 5.81 0.44 ± 0.02 −48.4 ± 1.19
NLC-8 30 285 30 200 83.63 ± 6.55 0.47 ± 0.04 −41.0 ± 2.35
NLC-9 20 270 15 300 309.86 ± 56.24 0.36 ± 0.06 −54.1 ± 4.36
NLC-10 30 270 15 300 182.7 ± 62.66 0.35 ± 0.04 −60.9 ± 1.64
NLC-11 20 285 15 300 108.2 ± 7.90 0.54 ± 0.02 −35.1 ± 1.01
NLC-12 30 285 15 300 86.37 ± 4.49 0.44 ± 0.02 −35.9 ± 5.68
NLC-13 20 270 30 300 135.86 ± 8.15 0.53 ± 0.02 −43.8 ± 1.46
NLC-14 30 270 30 300 119.8 ± 4.97 0.50 ± 0.08 −51.2 ± 0.86
NLC-15 20 285 30 300 166 ± 7.37 0.45 ± 0.03 −48.9 ± 4.37
NLC-16 30 285 30 300 157.63 ± 32.16 0.46 ± 0.17 −49.5 ± 0.94
3.1.1. Effects of Variables on the Mean Particle Size
The PS of formulations was in the range of 77.68 ± 2.29 nm to 309.86 ± 56.24 nm (Table 2).
Equation (4) shows factors A (homogenization time), B (solid lipid concentration) and C (liquid
lipid concentration) have a negative impact on PS of NLCs. Thus, increasing the homogenization
time (A) would significantly (p < 0.05) reduce the PS, possibly due to longer homogenization shear
force efficiently breaks the lipid globules into smaller particles. Similarly, increasing of solid lipid
concentration (B) would lower the surface tension of particle, and reduce the PS. This could be
attributed to Compritol 888 ATO® (solid lipid) that comprises mono- (12–18% w/w), di- (45–54% w/w)
and triglycerides (28–32% w/w) of fatty acid (C22 behenic acid) chains have surface active properties
which would reduce the surface tension, and therefore producing smaller NLCs [12,13]. Likewise,
the liquid lipid (C) also showed a significant negative impact (<0.05) on the PS, which could be
associated with the different viscosity of liquid and solid lipid. Thus, increasing the liquid lipid
concentration would drop the viscosity of NLCs, and reduce the surface tension, hence producing
smaller NLCs [14]. In contrast, surfactant concentration (D) had a positive effect on PS, increasing
its concentration would form larger NLCs. This could be due to the extra surfactant accumulated on
the outer surface of NLCs. The nonpolar alkyl chain loop and tail of the surfactant formed a bridge
in-between the nanoparticles, which might lead to aggregation [15–17]. The 3D response surface plot
(Figure 1) shows the positive impact of AB, AC, BC interactions and the negative impact of AD, BD
and CD interactions on PS of NLCs. The positive impact of AB interaction (increasing homogenization
time and solid lipid concentration) or AC interaction (increasing homogenization time and liquid lipid
concentration) or BC interaction (increasing solid lipid and liquid lipid concentrations) would increase
the PS of NLCs, and form larger PS of NLCs. While the negative impact of AD interaction (increasing
the homogenization time and surfactant concentration) or BD interaction (increasing solid lipid and
surfactant concentrations) or CD interaction (increasing liquid-lipid and surfactant concentrations)
would decrease the PS of NLCs, thus produced smaller PS of NLCs.
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Figure 1. 3D response surface plots showing the effect of interactions (a) AB, (b) AC, (c) AD, (d) CD,
(e) BD and (f) BC on the PS of NLCs. (A) Homogenization time, (B) solid lipid concentration, (C) liquid
lipid concentration, (D) surfactant concentration.
3.1.2. Effect of Variables on the Polydispersity Index (PdI)
The PdI values of all formulations were ranging from 0.35 ± 0.04 to 0.54 ± 0.02 (Table 2).
Equation (5) revealed factors B (solid lipid) and C (liquid lipid) have a positive impact on the PdI
of NLCs. Accordingly, increasing the solid lipid concentration (B) or liquid lipid concentration (C)
would increase the PdI significantly (p < 0.05). This could be due to the amount of surfactant was not
sufficient to reduce the surface tension caused by increasing the lipid concentration, hence formed
less homogeneous nanoparticles. Figure 2 shows the 3D response surface plot of the positive effect
of AC, BC, BD and CD interactions on PdI of NLCs. The positive effect of AC interaction (increasing
homogenization time and liquid lipid concentration) or BC interaction (increasing solid lipid and
liquid lipid concentrations) or BD interaction (increasing solid lipid and surfactant concentrations),
or CD interaction (increasing liquid lipid and surfactant concentration) would increase the PdI of
NLCs, hence formed less homogenous nanoparticles.
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Figure 2. 3D response surface plots showing the effect of interactions between (a) CD, (b) AC (c) BC
and (d) BD on the PdI of NLCs. (A) homogenization time, (B) solid lipid concentration, (C) liquid lipid
concentration, (D) surfactant concentration.
3.1.3. Effect of Variables on the Zeta Potential (ZP)
The ZP values of formulations were in the range from −33.2 ± 0.91 to −60.93 ± 1.64 mV (Table 2).
The NLCs have the negative charge of ZP due to the ionization of glyceryl behenate moiety (a fatty acid
in Compritol 888 ATO®). The homogenization time (A), solid lipid concentration (B) and surfactant
concentration (C) showed a significant effect (p < 0.05) on ZP. According to Equation (6), factor A
(homogenization time) showed a negative impact on ZP. Thus, prolonging homogenization time
would increase ZP value. This could be due to longer homogenization shear force would enhance the
ionization of glyceryl behenate. Similarly, factor D (surfactant concentration) also showed a negative
impact on ZP. Increasing the surfactant concentration would enhance the emulsification of solid lipid,
which led to higher ionization of glyceryl behenate moieties, hence increased ZP value. In contrast,
factor B (solid lipid) has the positive impact on ZP, thus increasing the amount of solid lipid would
reduce the ZP value, possibly due to incomplete emulsification of solid lipid by the available surfactant.
The negative impact of factors AD and DC interactions and the positive impact of BD interactions on
the ZP of NLCs are shown in the 3D surface plot (Figure 3). The negative impact of AD interaction
(increasing homogenization time and surfactant concentration) or DC interaction (increasing surfactant
and liquid lipid concentrations) would result in increasing the negative charge of the particles, hence
increased the ZP value of NLCs. The positive effect of BD interaction (increasing solid lipid and
surfactant concentration) would decrease the negative charge of nanoparticles thus decreased the ZP
value of NLCs.
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Figure 3. 3D response surface plots showing the effect of interactions (a) AD, (b) BD (c), DC on
ZP of NLCs. (A) homogenization time, (B) solid lipid concentration, (C) liquid lipid concentration,
(D) surfactant concentration.
3.1.4. Selection of NLC using the Desirability Function
The desirability function was used to select NLCs listed in Table 2. The following criteria, i.e.,
PS ≤ 150 nm, PdI ≤ 0.54 and ZP > −30 mV, was applied in the selection. The results showed that
the NLC-1, NLC-4, NLC-7, NLC-8, NLC-12 and NLC-14 formulations had the highest desirability
values of 0.824, 0.815, 0.816, 0.809, 0.815 and 0.752, respectively. The mean PS, PdI, and ZP of these
formulations were in the range of 83.63 ± 6.55 nm to 119.8 ± 4.97 nm, 0.42 ± 0.01 to 0.50 ± 0.08 and
−35.9 ± 5.68 mV to −51.23 ± 0.86 mV, respectively. Therefore, these formulations were selected for
further study.
3.2. Determination of Encapsulation Efficiency and Yield
The selected NLC-1, NLC-4, NLC-7, NLC-8, NLC-12 and NLC-14 formulations were further
studied by loading of 20 mg of LPV into NLCs (Table 3). It was found that the LPV-loaded NLCs
formulation (LPV-NLC-4, LPV-NLC-7, and LPV-NLC-8) had the % EE > 92% and % yield > 96%. Thus,
these formulations were further studied by incorporating of 30 and 35 mg of LPV. It was observed that
increasing the concentration of LPV to 35 mg had decreased the % EE significantly (p < 0.05). Therefore,
30 mg of LPV was considered the highest amount could be loaded in the NLCs. Based on the % EE and
% yield results, LPV-NLC-4, LPV-NLC-7, and LPV-NLC-8 formulations were selected for further study.
Table 3. Yield and entrapment efficiency of selected LPV-loaded NLCs formulations.
Formula Code Drug Added (mg) % Yield % Encapsulation Efficiency
LPV-NLC-1 20 97.58 ± 0.56 70.7 ± 2.15
LPV-NLC-4 20 97.16 ± 0.98 97 ± 1.25
LPV-NLC-7 20 98.44 ± 1.23 92.6 ± 3.20
LPV-NLC-8 20 96.27 ± 1.11 96.75 ± 4.11
LPV-NLC-12 20 99.41 ± 0.68 81.1 ± 2.27
LPV-NLC-14 20 98.75 ± 0.75 83.35 ± 1.98
LPV-NLC-4 30 98.24 ± 0.44 95.66 ± 1.15
LPV-NLC-7 30 96.46 ± 0.27 90.53 ± 0.70
LPV-NLC-8 30 97.20 ± 0.30 92.23 ± 2.70
LPV-NLC-4 35 97.22 ± 0.18 80.47 ± 1.64
LPV-NLC-7 35 97.06 ± 0.28 80.35 ± 0.97
LPV-NLC-8 35 96.62 ± 0.18 79.60 ± 2.07
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3.3. Freeze-Drying
Freeze-drying was conducted with the aim to improve the stability of LPV-NLCs by producing
solid formulation. Cryoprotectant was used to protect the LPV-NLCs during freeze-drying. Therefore,
several cryoprotectants were screened to evaluate their influence on PS and PdI of LPV-NLCs
(Table 4). Among the screened cryoprotectant, trehalose was found superior in preventing LPV-NLCs
aggregation during the freeze-drying process. Trehalose is cryoprotectant of choice for most of the
biomolecules because it has some advantages compared to other types of sugars, such as lower
hygroscopicity, less chemical interaction and lack of internal H-bonds which permits more flexible
H-bond formation with nanoparticles during freeze-drying. Additionally, trehalose was reported to
have a higher glass transition temperature which may help to prolong the nanoparticles stability and
also effective cryoprotectant for compritol 888 ATO® (glyceryl behenate) lipid-based nanoparticles
during freeze-drying [18,19].
Table 4. Screening of cryoprotectants.
Cryoprotectants Ratio (Lipid:
Cryoprotectant)
Before Lyophilization After Lyophilization
PS (nm) PdI PS (nm) PdI
Mannitol
1:2
99.5 ± 0.900 0.309 ± 0.047
NM 1
1:4 1799.9 ± 483.9 0.924 ± 0.132
1:6 1901 ± 305.1 1
1:8 1544.2 ± 205.2 1
Sorbitol
1:2 NM 1
1:4 NM 1
1:6 NM 1
1:8 NM 1
Sucrose
1:2 837.0 ± 186.1 0.537 ± 0.411
1:4 897.9 ± 72.5 0.913 ± 0.151
1:6 965.2 ± 196.7 1
1:8 1028.0 ± 125.9 1
Trehalose
1:2 744.2 ± 210.1 0.460 ± 0.300
1:4 383.7 ± 19.2 0.586 ± 0.370
1:6 463.1 ± 4.7 0.512 ± 0.215
1:8 478.4 ± 13.8 0.591 ± 0.030
Abbreviations: NM, not measurable.
Freeze-drying of LPV-NLC-4, LPV-NLC-7 and LPV-NLC-8 formulations without trehalose
produced a dried sticky sample with poor flowability, and difficult to redisperse in water. PS and
PdI of the freeze-dried formulations were increased significantly (p < 0.05), but there was no change
in %EE compared to the formulations before freeze drying (Table 5). In contrast, incorporation
of different concentrations of trehalose after homogenization process had produced free-flowing
formulations after tapping the bottle. The PS, PdI, and %EE of LPV-NLC-4-Tres, LPV-NLC-7-Tres
and LPV-NLC-8-Tres significantly reduced (p < 0.05) in comparison to the freeze-dried formulations
without trehalose. However, the addition of trehalose during homogenization had improved the %EE
of formulations significantly (p < 0.05) compared to the addition of trehalose after homogenization. The
LPV-NLC-7-Tres formulation had the lowest PS (286.8 ± 1.30nm) and the highest %EE (88.31 ± 2.04%)
at the lipid: trehalose ratio of 1:4 (Table 6). The PS of LPV-NLC-7-Tres was significantly smaller
(p < 0.05) than LPV-NLC-7. Increasing the size of LPV-NLC-7 could be due to the aggregation of
nanoparticles during the freeze-drying process. The lower %EE of LPV-NLC-7-Tres compared to
the LPV-NLC-7 could be due to the detachment of LPV from the outer surface of LPV-NLC-Tres
Pharmaceutics 2019, 11, 97 12 of 19
formulations (Table 5). Therefore, lipid: trehalose 1:4 ratio was used in the preparation of freeze-dried
LPV-NLC-4-Tres, LPV-NLC-7-Tres and LPV-NLC-8-Tres formulations for further investigation.
Table 5. Influence of cryoprotectant addition after homogenization process on PS, PdI, ZP and %EE.
Formula Code Ratio (Lipid:Trehalose) PS (nm) PdI ZP (mV) % EE
Before Freeze Drying
LPV-NLC-4 1:0 93.6 ± 0.4 0.307 ± 0.016 −43.6 ± 1.45 96.87 ± 0.76
LPV-NLC-7 1:0 104.3 ± 0.6 0.383 ± 0.012 −48.2 ± 1.50 91.72 ± 0.68
LPV-NLC-8 1:0 92.5 ± 0.6 0.315 ± 0.030 −42.5 ± 1.50 93.72 ± 0.96
After Freeze Drying
LPV-NLC-4 1:0 NM 1 −42.5 ± 0.53 95.66 ± 1.15
LPV-NLC-4-Tres
1:1 606.4 ± 98.9 0.361 ± 0.428 −42.7 ± 0.36 71.91 ± 3.03
1:2 472.3 ± 698.8 0.758 ± 0.210 −43.3 ± 1.49 68.99 ± 1.86
1:4 399.4 ± 1.5 0.720 ± 0.062 −42.3 ± 1.38 68.67 ± 0.60
1:6 487.5 ± 8.6 0.233 ± 0.112 −41.6 ± 1.45 82.61 ± 1.80
LPV-NLC-7 1:0 NM 0.603 ± 0.447 −47.1 ± 1.00 90.53 ± 0.70
LPV-NLC-7-Tres
1:1 1381.1 ± 383.2 0.898 ± 0.176 −45.4 ± 0.95 69.80 ± 1.87
1:2 859.8 ± 330.4 0.649 ± 0.501 −46.6 ± 1.25 68.13 ± 1.4
1:4 402.9 ± 11.7 0.277 ± 0.052 −48.2 ± 1.75 71.49 ± 2.14
1:6 445.0 ± 51.4 0.531 ± 0.152 −46.3 ± 1.80 78.76 ± 1.60
LPV-NLC-8 1:0 NM 1 −41.4 ± 1.27 92.23 ± 2.70
LPV-NLC-8-Tres
1:1 472.0 ± 2.3 0.342 ± 0.199 −41.3 ± 1.21 66.77 ± 3.70
1:2 398.6 ± 2.4 0.295 ± 0.143 −42.7 ± 0.47 64.25 ± 1.95
1:4 386.5 ± 9.7 0.296 ± 0.026 −42.5 ± 0.80 61.05 ± 1.86
1:6 425.4 ± 1.6 0.399 ± 0.059 −40.6 ± 0.83 66.44 ± 1.94
Abbreviations: NM, not measurable; LPV-NLC-4, LPV-NLC-7 and LPV-NLC-8 formulations without trehalose;
LPV-NLC-4-Tres, LPV-NLC-7-Tres and LPV-NLC-8-Tres formulations containing trehalose.
Table 6. Influence of cryoprotectant addition during homogenization process on PS, PdI, ZP and %EE.
Formula Code
Ratio (Lipid:
Trehalose)
After Freeze Drying
PS (nm) PdI ZP (mV) % EE
LPV-NLC-4-Tres
1:1 935.5 ± 1.50 0.468 ± 0.032 −43.8 ± 2.96 79.12 ± 1.32
1:2 750.2 ± 1.20 1 −41.5 ± 1.24 78.43 ± 3.21
1:4 337.5 ± 8.00 0.475 ± 0.145 −41.7 ± 1.15 79.38 ± 5.93
1:6 920.4 ± 2.50 0.798 ± 0.211 −42.6 ± 0.78 84.54 ± 1.17
LPV-NLC-7-Tres
1:1 NM 1 −48.2 ± 0.95 80.32 ± 1.33
1:2 969.9 ± 1.90 1 −47.3 ± 1.00 79.54 ± 3.24
1:4 286.8 ± 1.30 0.413 ± 0.017 −48.6 ± 0.89 88.31 ± 2.04
1:6 775.5 ± 160.11 0.957 ± 1.21 -46.6 ± 0.50 89.15 ± 4.33
LPV-NLC-8-Tres
1:1 1244.6 ± 536.36 1 -42.2 ± 0.95 76.23 ± 2.67
1:2 1082.52 ±483.93 1 -41.6 ± 0.98 75.24 ± 3.28
1:4 335.8 ± 3.10 0.525 ± 0.037 -40.6 ± 0.55 84.93 ± 1.62
1:6 870.42 ± 343.70 1 -42.6 ± 1.45 77.43 ± 4.94
Abbreviations: NM, not measurable; LPV-NLC-4-Tres, LPV-NLC-7-Tres and LPV-NLC-8-Tres formulations
containing trehalose.
Pharmaceutics 2019, 11, 97 13 of 19
3.4. In Vitro Release Study
The release profile of LPV-NLC-4-Tres, LPV-NLC-7-Tres, and LPV-NLC-8-Tres in the SIF and
SGF media showed more than 80% of LPV was released from the formulations (Figure 4a,b).
The formulations showed a burst release pattern, and about 45% of LPV was released within 5 min
and followed by a prolonged release in both release media. On the other hand, the LPV suspension
showed 9.01 ± 1.41% and 9.65 ± 0.31% dissolution in the SIF and SGF media within 12 h, respectively.
Figure 4. Comparison of LPV release from LPV-NLC-4-Tres, LPV-NLC-7-Tres, LPV-NLC-8-Tres, and
LPV -suspension for 12 h in (a) SGF (pH 1.2) and (b) SIF (pH 6.8) media. Mean ± S.D, n = 3.
The initial burst release of LPV from the LPV-NLC-Tres may be attributed to factors such as
nanoparticles size provided a large surface area to the LPV-NLC-Tres formulation and also deposition
of the attached LPV on the outer surface of the formulation. The latter might have occurred after the
hot homogenization process whereby, the melted lipid first solidified and formed a central core of lipid
and deposited some of the LPV on the outer surface of the lipid core. This, would provide a shorter
diffusion distance for LPV released from the formulation surface into the media, which resulted in
the burst release [20]. In addition, the presence of surfactants (poloxamer 188 and Tween® 80) in the
LPV-NLC-Tres formulation had facilitated the LPV release, while the nanosize range of particles in
the formulation had contributed in enhancing the LPV solubility. In contrast, the LPV-suspension is
hydrophobic in nature, thus it showed a limited solubility even in the presence of 1% poloxamer 188 in
the release medium. Among the LPV-NLC-Tres formulations, the LPV-NLC-7-Tres showed the highest
release (~97%) in both media and was selected as an optimized formulation for further study.
3.5. Differential Scanning Calorimetry (DSC)
DSC thermograms of bulk compritol 888 ATO®, poloxamer 188, LPV and trehalose exhibited
melting peaks at 73.72 ◦C, 50.80 ◦C, 96.97 ◦C, and 100.43 ◦C, respectively (Figure 5). The thermogram
of blank formulation, LPV-NLC-7, LPV-NLC-7-Tres showed that the Compritol 888 ATO®, poloxamer
188 and trehalose peaks in the formulation have shifted to 70.68 ◦C, 46.16 ◦C and 96.05 ◦C, respectively.
The shifting of peaks to lower values might be attributed to a reduction in particle size associated with
an increase in surface area and resulted in a decrease of enthalpy [15]. The thermogram of LPV-NLC-7
formulation was performed to find out whether the endothermic peak at 96.05 ◦C belongs to LPV
and/or trehalose. The thermogram showed that there was no endothermic peak appeared at 96.05◦C.
Thus, this finding confirmed that the endothermic peak at 96.05 ◦C position in the thermogram of
LPV-NLC-7-Tres formulation belongs to trehalose. The LPV endothermic peak was not noted in the
thermogram of LPV-NLC-Tres formulation and LPV-NLC-7, which might be due to the LPV solubility
had increased within the lipid matrix [1].
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Figure 5. DSC thermograms scanned from 0 to 150 ◦C at a rate of 10 ◦C/min for (a) Compritol 888
ATO®, (b) Poloxamer 188, (c) Trehalose, (d) LPV, (e) Physical mixture (i.e., Compritol 888 ATO®,
Poloxamer 188, trehalose and LPV), (f) Blank formulation, (g) LPV-NLC-7-Tres formulation, and (h)
LPV-NLC-7 formulation.
3.6. Wide Angle X-ray Scattering
The WAXS θ/2θ scans of LPV, compritol 888 ATO®, trehalose, blank formulation and
LPV-NLC-7-Tres are shown in Figure 6. The LPV spectrum showed quite sharp and definite diffraction
peaks at 10.4◦, 15.4◦, 18.8◦ and 22.6◦, anticipated a crystalline nature [3]. However, these diffraction
peaks have diminished in LPV-NLC-7-Tres formulation. This could be due to a reduction in the LPV
crystallinity or increasing its amorphous state, suggested the enhancement of its solubility in lipids.
Compritol 888 ATO® showed sharp peaks at 21.1◦ and 23.3◦ angles, but the peaks were reduced in the
LPV-NLC-7-Tres formulation due to polymorphic crystalline transformations of lipid (compritol 888
ATO®) upon heating. Aji Alex et al., reported a similar finding of LPV loaded in compritol 888 ATO®
based SLNs, whereby LPV decreased its crystallinity when loaded in SLNs. This suggested that the
solubility of LPV had increased in the glyceryl behenate [1]. The crystalline peaks of trehalose at 8.72◦,
15.27◦, 21.07◦, 23.87◦, 26.32◦, 27.52◦, and 31.62◦ were reduced in the LPV-NLC-7-Tres formulation as
compared to pure trehalose because it had formed an amorphous matrix with water molecules around
the nanoparticles during freezing [21].
Figure 6. PXRD patterns scanned from 2◦ to 60◦ 2θ at a rate of 5 ◦C/min for (a) Freeze-dried
LPV-NLC-7-Tres formulation, (b) Blank formulation, (c) Trehalose, (d) Compritol 888 ATO® and
(e) LPV.
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3.7. Evaluation using the Electron Microscope
The morphology of LPV-NLC-7 formulation before freeze-drying and after freez- drying was
examined using transmission electron microscopy (TEM) and scanning electron microscopy (SEM),
respectively. The nanoparticle of LPV-NLC before freeze-drying observed under TEM showed a
spherical shape with the size of ~100nm. In contrast, the nanoparticles of freeze-dried LPV-NLC-7
(without trehalose) examined under SEM revealed that the particles had diffused and loss of
their structure (Figure 7). However, freeze-drying of the formulation in the presence of trehalose
(LPV-NLC-7-Tres) showed that the structure of particle was still preserved and the size of nanoparticle
was ~200 nm.
Figure 7. (a) TEM image of LPV-NLC-7 before freeze-drying; (b) SEM image of LPV-NLC-7 after freeze
drying, and (c) SEM image of LPV-NLC-7-Tres after freeze drying.
3.8. Cellular Uptake of Optimized LPV-NLC-7-Tres Formulation
The monolayer model of the Caco-2 cell line is a popular model used for the investigation of
drug cellular uptake across the intestinal epithelium cells [22]. Some researchers reported the in vitro
cytotoxicity of commonly used excipients in pharmaceutical formulations namely Compritol 888
ATO [23], oleic acid [24,25], Tween® 80 [26,27] and poloxamer 188 [28]. These excipients were also
used in the present study. The maximum concentration of excipients, the cell line type and cell density
used in the present study were within the safety range of their study. The maximum concentrations
of Compritol 888 ATO®, oleic acid, Tween® 80 and poloxamer 188 used in the present study were
285 mg, 30 mg, 150 mg, and 150 mg respectively. The reported oral LD50 of Compritol 888 ATO®,
oleic acid, Tween® 80 and poloxamer 188 were 5000 mg/kg, 25,000 mg/kg, 25,000 mg/kg and 42,200
mg/kg, respectively [29,30]. Thus, based on the above reports the concentrations of excipient used in
the present study were also safe for the oral administration.
The present study showed that the Caco-2 cellular uptake was dependent on the concentration
of LPV, whereby increasing the LPV concentration would increase its cellular uptake. Figure 8
shows the LPV cellular uptake from LPV-NLC-7-Tres and LPV suspension enhanced significantly
(p < 0.05) from 2.17 µg/mL to 3.50 µg/mL and from 0.267 µg/mL to 0.555 µg/mL, respectively
when LPV concentration was increased from 8.52 µg/mL to 25.58 µg/mL. The LPV cellular uptake
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from LPV-NLC-7-Tres was 6.30-fold higher than the LPV suspension. Higher cellular uptake of
LPV-NLC-7-Tres could be due to increasing LPV solubility in the NLC formulation.
Figure 8. Comparison of LPV cellular uptake from LPV-NLC-7-Tres and LPV-suspension in Caco-2
cells. Mean ± SD, n = 3.
3.9. Stability Studies
The physical appearance of freeze-dried LPV-NLC-7-Tres samples stored at 5 ± 3 ◦C (refrigerated
condition) was preserved, including flowability and ease of redispersion up to a six-month study
period. Table 7 shows the PdI and ZP were not significantly changed (p > 0.05), but the PS was
significantly increased (~40 nm), while the drug content was significantly reduced (~1.5%). In contrast,
the samples stored at 25 ± 2 ◦C/60 ± 5% RH and 40 ± 2 ◦C/75 ± 5% RH conditions were found in
aggregated compact solid form. When the samples were reconstituted in distilled water, the particles
were difficult to re-disperse and aggregation was clearly seen visually. The PS and PdI were not
measurable (NM) and the drug content decreased significantly (p < 0.05).
Table 7. The stability of optimized LPV-NLCs-7-Tres formulation stored at 5 ± 3 ◦C, 25 ± 2 ◦C/60 ±
5% RH and 40 ± 2 ◦C/75 ± 5% RH (n = 3).
Stability at 5± 3 ◦C
Parameters 0 month 1 month 3 months 6 months
PS (nm) 255.8 ± 1.4 275.5 ± 5.7 286.5 ± 11.2 292.5 ± 9.8
PdI 0.531 ± 0.085 0.589 ± 0.115 0.543 ± 0.112 0.552 ± 0.112
ZP (mV) −48.50 ± 0.60 −48.30 ± 1.51 −47.10 ± 1.20 −47.50 ± 2.75
Drug content (%EE) 100.06 ± 0.07 99.93 ± 0.66 98.91 ± 0.61 97.82 ± 0.62
Stability at 25± 2 ◦C/60± 5% RH
Parameters 0 month 1 month 3 months 6 months
PS (nm) 255.8 ± 1.4 800.6 ± 159.31 NM NM
PdI 0.531 ± 0.085 1 NM NM
ZP (mV) −48.50 ± 0.60 −45.50 ± 1.63 −47.50 ± 1.42 −42.10 ± 2.66
Drug content (%EE) 100.06 ± 0.069 92.89 ± 1.008 88.93 ± 0.372 84.61 ± 0.715
Stability at 40± 2 ◦C/75± 5% RH
Parameters 0 month 1 month 3 months 6 months
PS (nm) 255.8 ± 1.4 933.93 ± 312.01 NM NM
PdI 0.531 ± 0.085 1 NM NM
ZP (mV) −48.50 ± 0.60 −46.90 ± 1.77 −45.60 ± 1.20 −45.70 ± 3.65
Drug content (%EE) 100.06 ± 0.07 76.64 ± 0.62 71.32 ± 5.53 68.54 ± 11.74
Abbreviations: NM, not measurable.
Pharmaceutics 2019, 11, 97 17 of 19
3.10. Oral Bioavailability Study
The mean plasma concentration-time plot of LPV-NLC-7-Tres and LPV suspension are depicted
in Figure 9. The concentration of LPV-NLC-7-Tres was higher than the LPV suspension in the
plasma following oral administration. The Cmax value of LPV-NLC-7-Tres (990.1 ± 264.7 ng/mL),
was significantly higher (p < 0.05) than the LPV suspension (158.3 ± 18.5 ng/mL). The AUC0-∞ value
of LPV-NLC-7-Tres (14635.1 ± 3847.5) was significantly (p < 0.05) higher than the LPV suspension
(2094.5 ± 73.8). Thus, based on the AUC0–∞ value obtained, the bioavailability of LPV-NLC-7-Tres
was 6.98-fold higher than the LPV suspension. The higher Cmax and AUC0-∞ of LPV-NLC-7-Tres
formulation could be due to an increase of LPV solubilization in the lipid matrix of the NLCs
system. The result is in agreement with the finding in the cellular uptake experiment. In addition,
the LPV-NLC-7-Tres has possibly bypassed the hepatic metabolism, and entered the lymphatic system.
The lower Cmax value of LPV-suspension might be due to LPV has low solubility, undergone extensive
hepatic metabolism, and high pg-efflux. The LPV-NLC-7-Tres contains lipids (Compritol 888 ATO®
and oleic acid), thus, it might have passed the primary routes of lipid transport across the intestinal
walls e.g., via transcellular absorption, paracellular transport, and stimulating chylomicrons secretion.
The Tmax of LPV-NLC-7-Tres (1 h) was significantly (p < 0.05) shorter than LPV suspension (2 h),
which might be due to higher absorption of LPV via NLCs. The t1/2 of LPV-NLC-7-Tres (16.5 ± 2.36 h)
was significantly (p < 0.05) longer than the LPV-suspension (5.4 ± 0.904 h). The elimination rate (Ke)
of LPV-NLC-7-Tres (0.0421 ± 0.007/h) was significantly (p < 0.05) slower than the LPV-suspension
(0.121 ± 0.021/h), which indicated longer elimination of LPV from LPV-NLC-7-Tres formulation.
Therefore, based on the pharmacokinetics results (Table 8), the present study had shown that NLCs
enhanced the oral bioavailability of protease inhibitor drug, LPV.
Figure 9. Comparison of LPV mean plasma concentration for 24 h following oral administration of
LPV-NLC-7-Tres and LPV-suspension in rats. Mean ± S.D, n = 6.
Table 8. Pharmacokinetic parameters of LPV-NLC-7-Tres and free LPV-suspension after oral
administration.
Formulation
Pharmacokinetic Parameters
AUC0-∞ ± SD
(ng-h/mL)
Cmax ± SD
(ng/mL) Tmax ± SD (h) t1/2 ± SD (h) Ke ± SD (h
−1)
LPV-NLC-7-Tres 14635.1 ± 3847.5 990.1 ± 264.7 1 ± 0.00 16.5 ± 2.36 0.0421 ± 0.007
Free LPV-suspension 2094.5 ± 473.8 158.3 ± 18.5 2 ± 0.00 5.4 ± 0.904 0.121 ± 0.021
Abbreviations: AUC0-∞, area under the plasma concentration-time curve; Cmax, maximum plasma concentration;
Tmax, time taken to reach maximum plasma concentration; t1/2, elimination half-life; Ke, elimination rate.
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4. Conclusions
The freeze-dried formulation of lopinavir-loaded nanostructured lipid carriers (LPV-NLC-7-Tres)
was successfully developed and optimized using a 24 full factorial design. The formulation had
high cellular uptake and oral bioavailability. The enhancement of the oral bioavailability of lopinavir
could be due to an increase in its solubility in the lipid matrix, and possibly bypass the hepatic
metabolism and absorbed through the lymphatic system. The formulation was relatively stable under
the refrigerated condition for six months.
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